An international, interlaboratory ring trial confirms the feasibility of an open source, extraction-less "direct" RT-qPCR method for reliable detection of SARS-CoV-2 RNA in clinical samples

4 Margaret G. Mills^{1¶}, Emily Bruce^{2¶}, Meei-Li Huang¹, Jessica W. Crothers², Ollivier Hyrien³, Christopher

5 A. L. Oura⁴, Lemar Blake⁴, Arianne Brown Jordan⁵, Susan Hester⁶, Leah Wehmas⁶, Bernard Mari⁷, Pascal

6 Barby⁷, Caroline Lacoux⁷, Julien Fassy⁷, Pablo Vial⁸, Cecilia Vial⁸, Jose R.W. Martinez⁸, Olusola

7 Olalekan Oladipo⁹, Bitrus Inuwa¹⁰, Ismaila Shittu¹⁰, Clement A. Meseko¹⁰, Roger Chammas¹¹, Carlos

8 Ferreira Santos¹², Thiago José Dionísio¹², Thais Francini Garbieri¹², Viviane Aparecida Parisi¹², Maria

9 Cassia Mendes-Correa¹³, Anderson V. dePaula¹³, Camila M. Romano¹³, Luiz Gustavo Bentim Góes^{14,15},

10 Paola Minoprio¹⁴, Angelica C. Campos¹⁴, Marielton P. Cunha¹⁴, Ana Paula P. Vilela¹⁴, Tonney

11 Nyirenda¹⁶, Rajhab Sawasawa Mkakosya¹⁶, Adamson S. Muula¹⁷, Rebekah E. Dumm¹⁸, Rebecca M.

12 Harris¹⁸, Constance A. Mitchell¹⁹, Syril Pettit^{19*}, Jason Botten^{2,20*}, and Keith R. Jerome^{1,3*}

13 ¹Virology Division, Department of Laboratory Medicine and Pathology, University of Washington,

- 14 Seattle, Washington, USA
- ²Division of Immunobiology, Department of Medicine, Robert Larner, M.D. College of Medicine,
- 16 University of Vermont, Burlington, Vermont, USA

17 ³Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington,

18 USA

⁴School of Veterinary Medicine, University of the West Indies, Trinidad and Tobago

- 20 ⁵Ministry of Health, Trinidad and Tobago
- ⁶Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park,
- 22 North Carolina, USA
- ⁷Université Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, FHU-OncoAge,
- 24 Valbonne, France

- 25 ⁸Programa Hantavirus, Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica
- 26 Alemana Universidad del Desarrollo, Santiago, Chile

27 ⁹Biochemistry Division, National Veterinary Research Institute, Vom, Nigeria

- 28 ¹⁰Infectious and Transboundary Animal Diseases, National Veterinary Research Institute, Vom, Nigeria
- 29 ¹¹Centro de Investigação Translacional em Oncologia, Departamento de Radiologia e Oncologia, Instituto
- 30 do Cancer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo,
- 31 Brazil
- 32 ¹²Bauru School of Dentistry, Department of Biological Sciences, University of São Paulo, Bauru, São
- 33 Paulo, Brazil
- 34 ¹³Department of Infectious Diseases, Institute of Tropical Medicine of São Paulo, São Paulo, Brazil
- 35 ¹⁴Scientific Platform Pasteur-USP, Universidade de São Paulo, São Paulo, São Paulo, Brazil
- ¹⁵Department of Microbiology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil
- ¹⁶Department of Pathology, College of Medicine, University of Malawi, Blantyre, Malawi
- 38 ¹⁷Department of Public Health, College of Medicine, University of Malawi, Blantyre, Malawi
- 39 ¹⁸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
- 40 ¹⁹Health and Environmental Sciences Institute, Washington, DC, USA
- 41 ²⁰Department of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine,
- 42 University of Vermont, Burlington, Vermont, USA
- 43 *Corresponding authors: spettit@hesiglobal.org (SP), jason.botten@uvm.med.edu (JB),
- 44 kjerome@uw.edu (KRJ).
- 45 [¶]These authors contributed equally to this work.

46 Abbreviations

47	CDC	Centers for Disease Control and Prevention
48	COVID-19	coronavirus disease
49	Ct	cycle threshold
50	FFU	focus forming unit
51	HESI	Health and Environmental Sciences Institute
52	IRB	institutional review board
53	N2	specific PCR target within SARS-CoV-2 nucleocapsid (N) gene
54	RNA	ribonucleic acid
55	RP	human RNase P gene
56	RT-PCR	real time-reverse transcription polymerase chain reaction
57	RT-qPCR	reverse transcription-quantitative polymerase chain reaction
58	SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
59	UWVL	University of Washington Virology Laboratory

60 Abstract

61 Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is used worldwide to test and 62 trace the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). "Extraction-less" or 63 "direct" real time-reverse transcription polymerase chain reaction (RT-PCR) is an open-access qualitative 64 method for SARS-CoV-2 detection from nasopharyngeal or oral pharyngeal samples with the potential to 65 generate actionable data more quickly, at a lower cost, and with fewer experimental resources than full 66 RT-qPCR. This study engaged 10 global testing sites, including laboratories currently experiencing 67 testing limitations due to reagent or equipment shortages, in an international interlaboratory ring trial. 68 Participating laboratories were provided a common protocol, common reagents, aliquots of identical 69 pooled clinical samples, and purified nucleic acids and used their existing in-house equipment. We 70 observed 100% concordance across laboratories in the correct identification of all positive and negative 71 samples, with highly similar cycle threshold values. The test also performed well when applied to locally 72 collected patient nasopharyngeal samples, provided the viral transport media did not contain charcoal or 73 guanidine, both of which appeared to potently inhibit the RT-PCR reaction. Our results suggest that open-74 access, direct RT-PCR assays are a feasible option for more efficient COVID-19 coronavirus disease 75 testing as demanded by the continuing pandemic.

76 **1. Introduction**

The global coronavirus disease (COVID-19) pandemic response depends on effective rollout of recently approved vaccines and the use of nonpharmaceutical interventions to slow the spread of the disease. Physical distancing supported by test-and-trace informed containment strategies has been promoted worldwide [1]. The effectiveness of testing as a containment strategy requires the implementation of accessible, affordable, reliable, and rapidly executable test methods that can meet the rapid pace of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission [2-4]. At present, this goal remains largely unmet.

84 The majority of regional and national health laboratories around the world rely on reverse 85 transcription-quantitative polymerase chain reaction (RT-qPCR) SARS-CoV-2 virologic testing methods 86 such as those developed by the World Health Organization and the U.S. Centers for Disease Control and 87 Prevention (CDC) to support their public health programs [5, 6]. The methods themselves are robust and 88 have proven to be useful standards for detection and reporting. However, sample processing time and a 89 lack of supplies to support extraction as required to run this type of assay have resulted in widely reported 90 backlogs and shortages in the United States and around the world [7]. In regions that also suffer from 91 systemic financial and logistical challenges (e.g., Africa, the Caribbean, and South America), these 92 hurdles will continue to consistently impair reliable procurement of consumables, support for staffing, 93 and thus testing viability [8, 9]. Although the diversity and efficiency of commercial virologic and 94 serologic test methods expands weekly, most public health laboratories lack the resources (human and 95 capital) or remit to pivot to novel commercial methods.

96 To address these challenges, the nonprofit Health and Environmental Science Institute (HESI)
97 convened an international network of public and academic COVID-19 testing laboratories — the
98 Propagate Network — with the goal of collectively evaluating and disseminating practical, efficient, and
99 impactful open-access methods for SARS-CoV-2 detection. The Propagate Network and others have
100 identified "extraction-less" or "direct" real time-reverse transcription polymerase chain reaction (RT-

101 PCR) as an open-access qualitative method for SARS-CoV-2 detection from nasopharyngeal samples 102 with the potential to generate actionable data more quickly, at a lower cost, and with fewer experimental 103 resources than full RT-qPCR [10, 11]. The method allows for detection of SARS-CoV-2 viral ribonucleic 104 acid (RNA) with the omission of the most labor-intensive step — the RNA extraction step — and its 105 associated extraction reagents. Published intralaboratory studies indicate that the technique is internally 106 reproducible (with some loss of sensitivity compared to standard RT-PCR) and is effective in detecting 107 both true negatives and positives. Notably, direct RT-qPCR remains sufficiently sensitive to detect viral 108 RNA from patients most likely to be infectious (cycle threshold [Ct] < 33) [12-15].

The major goal of this Propagate Network study was to determine the practical utility of an openaccess, direct RT-PCR assay [10] via an international, interlaboratory ring trial. The study engaged 10 global sites, including laboratories currently experiencing many of the testing limitations described above, in a series of studies involving a common protocol, common reagents, aliquots of identical pooled clinical samples, and purified nucleic acids, using their existing in-house equipment. Our results suggest that open-access, direct RT-PCR assays are a feasible option for more efficient COVID-19 testing as demanded by the growing pandemic.

116 **2. Materials and Methods**

117 **2.1 Participants**

The Propagate Network study was coordinated and partially funded by the international nonprofit
HESI as part of its global public health mission and via voluntary contributions of time and effort from
the participating partners. Special acknowledgment is given to the University of Washington Virology
Laboratory (UWVL) for their efforts to prepare and ship samples for this study and to the University of
Vermont Larner School of Medicine for their support in refining the study protocols and recruiting
partner laboratories.

Ten laboratories were recruited to participate in the trial for the detection of SARS-CoV-2 RNA from
patient nasopharyngeal swabs without RNA extraction using kits provided by UWVL (Table 1).

- 126 Laboratories participated voluntarily and were not offered any compensation for their participation. Due
- 127 to logistical shipping challenges, which were in large part brought on by the pandemic, samples were
- 128 unable to be sent to Malawi or Nigeria, underlying the hardships some areas face when testing relies on
- 129 reagents or materials from other countries.

130 Table 1. Institutions and Countries of the Laboratories Participating in the Trial.

Institution	Country	Role in Propagate Network	Laboratory Role in COVID-19 Testing Regionally
Department of Pathology, College of Medicine, University of Malawi	Malawi	Project C	Collaborating with government public health authorities to provide testing for local population
Bauru School of Dentistry, Department of Biological Sciences, University of São Paulo, Bauru, São Paulo, Brazil	Brazil	Projects A and B	Collaborating with government public health authorities to provide testing for local population and students. Laboratory component of the COVID-19 Diagnostic Network from the University of São Paulo
Department of Infectious Diseases, Institute of Tropical Medicine of São Paulo, São Paulo, Brazil	Brazil	Projects A, B, and C	Collaborating with government public health authorities to provide testing for local population and students. Laboratory component of the COVID-19 Diagnostic Network from the University of São Paulo
Scientific Platform Pasteur- USP, Universidade de São Paulo, São Paulo, São Paulo, Brazil	Brazil	Projects A, B, and C	Collaborating with government public health authorities to provide testing for local population and students. Laboratory component of the COVID-19 Diagnostic Network from the University of São Paulo
Biochemistry Division, National Veterinary Research Institute	Nigeria	Project C	Collaborating with government public health authorities to provide testing for local population
Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile	Chile	Projects A, B, and C	Collaborating with government public health authorities to provide testing for local population
Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur	France	Projects A and B	Basic science, testing developments

LBM Bioesterel	France	Projects A and B	Medical laboratory: processes thousands of samples daily for the south east region of France
School of Veterinary Medicine, University of the West Indies	Trinidad and Tobago	Projects A, B, and C	Collaborating with government public health authorities to provide testing for local population, returning residents, and migrants
Division of Immunobiology, Department of Medicine, Robert Larner, M.D. College of Medicine, University of Vermont	United States	Projects A, B, and C	Basic science, development of streamlined diagnostic RT-PCR assays for SARS-CoV-2 testing/screening in Vermont, determining how viral RNA load in clinical samples correlates with infectiousness
Office of Research and Development, U.S. Environmental Protection Agency	United States	Projects A and B	Not engaged in COVID-19 testing on a regular basis
University of Washington Virology Laboratory (UWVL), Virology Division, Department of Laboratory Medicine and Pathology, University of Washington	United States	Projects A and B; lead laboratory responsible for Project A/B sample preparation and dissemination	Processes thousands of samples daily for Pacific Northwest Region and elsewhere in the United States

132

133 **2.2 Ethical statement**

134 The samples generated and disseminated as part of Projects A and B were approved under a waiver of 135 consent by the University of Washington institutional review board (IRB; STUDY00000408). The de-136 identified samples were determined to be exempt because they were not considered human subjects 137 research due to the quality improvement and public health intent of the work. For Project C, participating 138 laboratories sought the locally appropriate review and permissions for use of de-identified clinical 139 samples as described below. 140 University of West Indies: Based on the Campus Research Ethics Committee at the University • 141 of West Indies, this research met the criteria for Exemption. This decision was made by the chair

of west lindles, this research met the criteria for Exemption. This decision was made by the cri

142 of the ethics committee, Professor Jerome De Liste.

Department of Infectious Diseases, Institute of Tropical Medicine of São Paulo: Sample use
 was approved by the local ethics committee (Comissão de Ética para Análise de Projeto de
 Pesquisa; protocol number CAAE 30419320.7.0000.0068). Informed consent was obtained from
 all the individuals enrolled in this study.

- National Veterinary Research Institute, Nigeria: This work and samples were approved for
 ethical use within the emergency response to COVID-19 control in Nigeria through rapid
 laboratory diagnosis. The National Veterinary Research Institute in accordance with the World
 Organization for Animal Health guidance offered its facility for Public Health Service in Nigeria
 following activation by the Nigerian Centre for Diseases Control of the Federal Ministry of
 Health.
- University of Malawi: Based on a review by the College of Medicine Research and Ethics
 Committee (COMREC), no IRB approval acknowledgments were required. This was reviewed by
 the COMREC administrator, Dr. Lucinda Manda-Taylor, and the compliance officer, Khama
 Mita.

University of Vermont: This work was approved under a waiver of consent by the University of
 Vermont IRB (STUDY00000881).

159 • Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana 160 Universidad del Desarrollo, Santiago, Chile: The study and publication of its data was 161 approved by a decision made by the Scientific Ethics Committee at the Center of Bioethics at the 162 College of Medicine on 17 March 2021 (as approved by Dr. Marcial Osorio (President of the 163 Scientific Ethics Committee) and Javiera Bellolio A. (Executive Secretary of the Scientific Ethics 164 Committee, College of Medicine, Center of Bioethics) upon review of the document 165 "Admin_Comp_200-53 Requests for Release of Clinical Specimens or Results", as well as this 166 manuscript. The committee made the statement "It is considered that, given the modality of the 167 study, where the identity is duly protected, and, given the importance from the public health point 168 of view, this project has been approved by the Committee for the publication of the data." The169 signed document can be provided upon request.

Bauru School of Dentistry, Department of Biological Sciences, University of Sao Paulo: Sample
 use approved by the Institutional Review Board of the Bauru School of Dentistry, University of
 Sao Paulo (CAAE # 32658720.4.0000.5417)

173 2.3 Study design

- 174 The Propagate ring trial consisted of three components. Projects A and B engaged participant
- 175 laboratories in the analysis of pooled samples disseminated from the lead laboratory (UWVL) for the
- 176 purpose of evaluating the cross-laboratory performance of the direct method with parallel (identical)
- 177 samples. Project C characterized the feasibility of the direct method as applied to locally sourced samples
- 178 collected as part of regional public health testing efforts (**Fig 1**).



- 180 Fig 1. Study Design for the Propagate Network.
- 181 All laboratories were invited to participate in Projects A, B, and C. Logistical challenges due to
- 182 COVID-related shipping restrictions prohibited the involvement of the Malawi and Nigeria laboratories in
- 183 Projects A and B.

Project A. To confirm that all reagents arrived safely and that every laboratory could perform the direct RT-PCR method, each laboratory tested a set of eight nucleic acid samples purified from patients with COVID-19 and supplied by UWVL, which included six blinded samples (three positive and three negative), one sample identified positive, and one sample identified negative to serve as controls, plus a laboratory-supplied no-template water control. Each laboratory reviewed the results of Project A with the study coordinator to confirm that they had correctly identified 100% of the positive and negative blinded samples before proceeding.

191 Project B. Each laboratory then tested a set of 34 samples supplied by UWVL, including 30 blinded 192 samples (25 positive CT and 5 negative) as well as 2 identified positive and 2 identified negative samples 193 as controls, plus a laboratory-supplied no-template water control. Results for all Project B samples were 194 shared with the study coordinator.

Project C. When and where possible, laboratories selected known-positive, locally collected clinical
samples and known-negative samples and tested each by both their standard extraction method and the
direct RT-PCR method. Results for all Project C samples were shared with the study coordinator.

198 **2.4 Heat inactivation**

To validate whether a 10-min heating step would inactivate infectious SARS-CoV-2 virus present in clinical samples, the University of Vermont team incubated high-titer stocks of authentic SARS-CoV-2 at 95°C (in a heat block) or room temperature in 1.5-ml Eppendorf tubes for 10 min, spun samples briefly in a microcentrifuge, then measured the infectious units remaining in the heat-treated samples versus the untreated controls by immunofocus assay [16]. The stock virus (strain

 $2019 \square nCoV/USA_USA \square WA1/2020 [WA1]) was graciously provided by Kenneth Plante and the World$

205 Reference Center for Emerging Viruses and Arboviruses at the University of Texas Medical Branch.

206 2.5 Sample preparation

Identical kits were prepared by UWVL and sent on dry ice to each participating laboratory. These kits
 included reagents for the three possible projects (Fig 1): blinded purified total nucleic acid samples plus

positive and negative controls (Project A); blinded unpurified patient samples plus positive and negative
controls (Project B); and sufficient enzyme, buffer, primers, and probes to test all samples for Projects A
and B, as well as local patient samples (Project C).

To make positive and negative control samples for the kits, nasopharyngeal patient samples in viral transport media were gathered from UWVL's clinical specimen collection. Three positive samples with a high concentration of SARS-CoV-2 viral RNA ($C_t \sim 15$) were pooled together and then diluted 1:32 in a pool of negative samples. Aliquots of positive pooled samples ($C_t \sim 20$) and of negative pooled samples were subjected to RNA extraction using a MagNA Pure LC (Roche) to generate purified positive and negative total nucleic acid for Project A.

The unpurified positive pool was diluted further in the negative pool to generate samples at 18
specific expected C_t values ranging from 21 to 32 for Project B. These de-identified and pooled samples,
both purified total nucleic acid and unpurified patient samples, were each divided into 50-µl aliquots.
Two aliquots with a C_t value of 21 were included as positive controls in each kit. A random number
generator was used to determine the order of blinded samples within the kits. All samples were tested in
parallel by direct RT-PCR method and by MagNA Pure LC nucleic acid extraction followed by RT-PCR
at UWVL to confirm negative samples and Ct range of positive samples.

225 **2.6 Testing method**

The direct RT-PCR method is described in Bruce et al. [10]. Briefly, 20 µl of each sample was heat
treated for 10 min at 95°C then vortexed and spun down. A Master Mix was made by combining 7 µl of

water, 12.5 µl of buffer mix, 1.5 µl of primer/probe mix (IDT), and 1 µl of AgPath-ID enzyme

229 (ThermoFisher) per reaction. Either in 96-well optical PCR plates or optical strip tubes, 22 µl of Master

230 Mix and 3 µl of heat-treated sample was added to each well or tube. All manipulations of clinical samples

- 231 (transfer for heat inactivation as well as loading of the RT-PCR plate) were performed in a class IIA
- biosafety cabinet following biosafety level 2 practices. The plates or tubes were then covered with an
- 233 optical adhesive cover or caps and spun down at 1000 rpm for 1 min. The RT-PCR reaction consisted of

10 min at 48°C for reverse transcription, 10 min at 95°C, and 40 cycles of 95°C for 15 s, followed by

- 235 60°C for 45 s with fluorescence measured at the end of each cycle. All samples were tested in duplicate,
- with water controls on each plate. Reactions to measure the SARS-CoV-2 N-gene (using CDC N2
- 237 primers and FAM-labeled probe) and human RNase P gene (using CDC RP primers and FAM-labeled
- probe) were carried out for each sample in parallel.

239 **2.7 Data collection and analysis**

For each sample, a mean C_t value was computed by averaging individual C_t values from all

241 laboratories. A Ct value residual (for a given laboratory and sample) was defined as the individual Ct

242 value minus the associated mean C_t value. For data visualization, individual C_t values and residual C_t

- 243 values were plotted against mean Ct values. Assay specificity and sensitivity was evaluated using the
- 244 negative and positive blinded samples.

245 **3. Results**

246 **3.1 Heat inactivation**

High-titer stocks of SARS-CoV-2 were treated at 95°C for 10 min. The stock virus had a titer of $>10^6$ focus forming units (FFUs) per milliliter. After heat treatment there was more than a 5-log drop, with no detectable foci after 10 min at 95°C (**Fig 2**).

heat inactivation



n=4

Fig 2. Heat Treatment Inactivates SARS-CoV-2. Stocks of SARS-CoV-2 split into aliquots were
treated at 95°C for 10 min or untreated. Viral titer was determined using a focus forming assay with an
antibody recognizing the viral N protein. Measurements are in focus forming units (FFU) per milliliter (*n*= 4 replicates). The limit of detection for this assay was 20 FFU/ml.

255 **3.2 Project A: laboratory qualification**

250

All participating laboratories correctly identified 100% of the positive (n = 3) and negative (n = 3)

257 blinded samples sent for purposes of confirming that the samples arrived safely and that the laboratory

258 was able to run the direct RT-PCR method.

259 **3.3 Project B: interlaboratory agreement using blinded samples**

260 Qualitative agreement between laboratories. The most critical performance measures of a SARS-

261 CoV-2 test are its sensitivity and specificity (simply put, the ability to accurately distinguish the presence

versus absence of the viral RNA) and the consistency of its performance across laboratories. As an initial

263 approach, assay specificity and sensitivity was evaluated using 5 known-negative and 25 known-positive

samples that were tested in a blinded fashion by the 10 laboratories. For the five negative samples, a total

of 50 values were reported by the laboratories, all of which were reported as negative for virus. Thus, the assay demonstrated consistently high (100%) specificity across the laboratories for negative samples (**Table 2**). For the 25 positive samples, the 10 laboratories reported a total of 250 C_t values. All of these but one were reported as positive. Thus, all 10 laboratories were able to correctly detect the virus in 24 of 25 samples, and 9 of 10 laboratories were able to correctly detect the virus in all 25 samples using the assay, yielding consistently high [99.6% = $(249/250) \times 100\%$] sensitivity across the 10 laboratories for positive samples.

Table 2. Specificity and Sensitivity of the Test Based on Results From 30 Blinded Samples (5 Negative and 25 Positive) and the 10 Laboratories.

		Test		
		Negative	Positive	
Trusth	Negative	50	0	
Iruin	Positive	1	249	

274

Quantitative agreement between laboratories. In addition to providing a qualitative determination of the presence versus absence of virus, RT-PCR tests for SARS-CoV-2 can provide additional value by reporting their C_t value, which serves as a proxy for the amount of viral RNA present. We therefore investigated the C_t values reported for the blinded positive samples tested by the participating laboratories. In general, the agreement between C_t values from different laboratories was good, with tighter agreement at lower average C_t (higher viral loads) than at higher average C_t (lower viral loads; **Fig 3**).



Fig 3. High Interlaboratory Agreement in C_t Values for Blinded Clinical Samples in Project B. C_t values plotted against the sample-specific average C_t values from the 10 laboratories. The solid line indicates the line of equation y = x. Each color indicates one laboratory; the same color is used to identify each laboratory in all subsequent figures.

287 We then evaluated the overall quantitative performance of each individual laboratory against the 288 sample-specific average C_t value as determined by all 10 laboratories. The C_t value residual for a given 289 laboratory and sample was defined as the Ct value for the corresponding laboratory and sample minus the 290 sample-specific average C_t value; the narrower their distribution within a laboratory, the more consistent 291 the relationship of C_t values from the laboratory with the average C_t value from all laboratories. Residual 292 Ct values had overall similar variability across samples and were minimally affected by the actual viral 293 load (Fig 4). The residuals appeared to be centered around zero for most laboratories (Fig 5), with the 294 exception of laboratories 3 and 7, for which residuals appeared systematically negative (indicative of C_t 295 values consistently lower than average), and laboratory 9, in which residuals tended to be positive 296 (indicative of C_t values consistently higher than average). There was no evidence that the assay had a 297 lower sensitivity in this particular laboratory.





Fig 4. Distribution of C_t Residuals Relative to Sample-Specific Average C_t Values. Residuals were consistent between laboratories regardless of viral load. Residuals were plotted against sample-specific average C_t values. Each colored dot represents a different participating laboratory per legend.



Fig 5. Distribution of Ct Value Residuals Plotted by Laboratory. Ct value residuals were calculated as
 the Ct values minus the sample-specific average Ct value.

305 **3.4 Project C: application of direct RT-PCR on locally collected clinical samples**

306 Seven Propagate partner laboratories conducted side-by-side comparisons of direct RT-PCR and 307 extraction RT-PCR on clinical samples collected from their regions. For four laboratories (2, 7, 8, and 308 10), these studies demonstrated average losses of sensitivity of between 1.5 and 3.8 cycles in RP C_t value 309 (Fig 6a; Table 3) and between 2.6 and 4.8 cycles in N2 Ct value (Fig 6b; Table 3), compared with direct 310 RT-PCR. For RP, this resulted in no failure to detect any sample from any of the four laboratories. For 311 samples in which N2 was detectable by both direct and extraction RT-PCR, the difference in C_t values 312 between the two methods did not correlate with the C_1 value obtained by either method (Fig 6c). 313 However, a few samples (6 of 93) that were detected between C_1 values of 28 and 39 by extraction RT-314 PCR were undetectable by direct RT-PCR, while other samples in that range were still detectable by the 315 same laboratories (Fig 6c).





317 Fig. 6. Comparison of Direct Versus Extracted PCR Analyses for Locally Sourced Clinical Samples

318 (Project C). The left (A) and center (B) boxplots illustrate the difference between direct and extracted Ct

319 values in the five laboratories participating in Project C for the RP and N2 genes respectively. The right

boxplot (C) illustrates the difference between direct and extracted Ct values plotted against the extractedCt value, in five laboratories.

323 Table 3. Difference in Sensitivity of Direct RT-PCR and Extraction RT-PCR Methods on Local

324 Samples From Five Laboratories.

	Lab 2	Lab 7	Lab 8	Lab 9	Lab 10	All labs
Samples (<i>n</i>)	20	30	10	4	29	93
Direct, extracted C_t (mean \pm SD)						
RP	2.5 ± 2.5	1.5 ± 1.9	3.1 ± 0.9	-0.3 ± 1.4	3.8 ± 2.2	2.5 ± 2.3
N2	4.3 ± 3.2	2.6 ± 2.0	2.6 ± 1.3	-1.6 ± 1.4	4.8 ± 2.3	3.4 ± 3.0

325

For laboratory 9, direct RT-PCR yielded lower Ct values for both RP and N2 than extraction RT-PCR, with an average difference of -0.3 cycles and -1.6 cycles, respectively (Table 3). The reason for this unexpected result is not clear, but it may have been related to the laboratory's observation that samples became "highly viscous" after the heating step (an observation not reported in any of the other participating laboratories). As with any method, the authors recommend internal validation of the approach prior to clinical implementation.

332 For two laboratories, direct amplification of both N2 and RP was unsuccessful in all samples,

including for samples with low N2 C_t values (high viral loads) as measured by extraction RT-PCR. These

334 samples were later determined to have been collected in transport media containing ingredients that were

inhibitory to PCR, including charcoal and guanidine (e.g., ManTacc UTM and Jiangsu Rongye

336 Technology LinkGen media were reported as incompatible). Information on the brand/type of viral

337 transport media was not available for all samples used in Project C (this information is often not reported

338 with swabbed samples as provided to analysis laboratories). However, the following media were

339 specifically identified as compatible with this method (Hardy viral transport media, saline, and phosphate-

340 buffered saline).

341 Overall, the direct approach worked effectively to detect samples deemed positive by standard RT-

342 qPCR when samples were collected in media lacking charcoal or guanine.

343 **4. Discussion**

This study confirms that the direct RT-qPCR method, initially described by Bruce et al. [10], has the potential to meaningfully contribute to global efforts to detect and contain the COVID-19 pandemic. This study provides evidence that the direct RT-qPCR method is an efficient, reliable, and achievable method for detection of SARS-CoV-2. Although the reproducibility of the method has been reported in single-

348 laboratory studies previously, this study is the first to demonstrate that a globally diverse set of

349 laboratories operating with different equipment, clinical sample collection and handling conditions,

350 resource limitations, and operating practices can successfully implement the method.

351 As described above, when centrally disseminated pooled samples were evaluated with a common 352 Master Mix and primers/probes (Projects A and B), the Propagate partner laboratory results were >99.5% 353 concordant (all negatives and all but one positive correctly identified and strong agreement on C_t values). 354 This result demonstrates the robustness of the methodology. Although all Propagate partner laboratories 355 had prior experience with standard RNA extraction RT-PCR analysis of SARS-CoV-2 test samples, they 356 were able to adopt and implement the direct method on Project A and B samples with only a minimum of 357 instruction (a brief written protocol and a few minutes of discussions via web meeting), showing that the 358 method is easily transferable. Due to halts and delays in air shipments, the partner laboratories in Malawi 359 and Nigeria were unable to receive or analyze the Project A/B sample kits. While this was unfortunate, it 360 is emblematic of the challenges that the African continent (among others) continues to face in receiving 361 needed laboratory supplies and the importance of resource-sensitive methods development efforts such as 362 these.

In Project C of this study, Propagate partner laboratories were encouraged to use their own extraction
methods and locally collected samples with RT-qPCR reagents supplied by UWVL to compare results
from the direct method versus standard extraction-based PCR. The majority of the participating partner
laboratories were successfully able to apply the method and reliably detect RT-PCR-positive samples.
The importance of "ground testing" new methods was made evident when some of the laboratories were

368 unable to detect any signal (N2 or RP) following the direct method despite using high-titer positive 369 samples as detected by standard methods. Laboratories experiencing this problem in some cases were 370 working with samples collected in commercial viral transport media that were often found to contain 371 charcoal or in inactivating media such as those containing guanidine. We hypothesize that these are 372 inhibitory to the RT-PCR reaction in the absence of an extraction phase. Similar inhibitory outcomes have 373 been subsequently identified by other laboratories [11, 17]. In other cases, the constituents of media were 374 unknown, so we were not able to hypothesize why the direct method was incompatible. We recommend 375 that laboratories seeking to employ the direct method for SARS-CoV-2 detection should conduct a small 376 pilot run (comparing results from direct and full PCR analyses on the same samples) to ensure that sample 377 media are compatible with this method. This pilot should be replicated if/when sample collection methods 378 or media are changed.

379 The success of this ring trial is of critical importance given the growing calls for COVID-19 380 screening as a containment strategy. The growing pandemic requires that we supplement definitive 381 clinical testing with scalable screening strategies that generate efficient, reliable results that can readily 382 inform public health action (e.g., quarantine and isolation) [2]. Non-PCR immunoassay antigen screening 383 kits have decreased sensitivity as compared to standard PCR but are widely utilized depending on the 384 country's COVID-19 pandemic testing strategy [18]. As anticipated per previous studies, the direct 385 method as applied to SARS-CoV-2 results in some loss in sensitivity compared to standard PCR. One 386 primary explanation for this observation is that RNA extraction typically concentrates RNA present in the 387 clinical sample (by eluting the sample in a smaller volume. In addition, there is a low level of inhibition 388 seen in clinical NP samples loaded directly into an RT-PCR reaction, and the sensitivity of the approach 389 drops when more than 3 ul of patient sample is used [10]. However, this loss is of lower significance to 390 the method's potential value as a public health screening tool. The direct method succeeds in all of the 391 areas of greatest contemporary need: 1) it reliably detects samples with RNA levels correlating to the 392 presence of live virus (and thus most potential for infectivity), 2) it provides the potential to optimize 393 throughput and reduce costs/logistics for SARS-CoV-2 testing, 3) it is an open-access methodology with

394 no commercial barriers or de novo equipment investment hurdles, and 4) it can be readily adopted by 395 most current public health or clinical laboratories with experience handling infectious samples [14, 15]. 396 We believe that the direct RT-qPCR method for SARS-CoV-2 screening is ripe for adoption in 397 laboratories seeking to reduce turnaround time for processing samples, experiencing challenges in 398 accessing extraction reagents, seeking to decrease costs, and/or looking to reduce the use, handling, and 399 disposal of chemicals in their laboratory. We do not propose this method as a substitute for samples 400 requiring ultrasensitive detection. As with the adoption of any new method, appropriate validation must 401 be conducted by the host laboratory. As standard RNA extraction reagents for PCR can cost \$5-\$6 USD 402 per extraction and millions of these tests are performed each day around the world, the potential savings 403 are significant. The utilization of this method could lead to greater testing coverage of individuals per 404 dollar invested, or alternatively a larger number of examinations per individual, either of which would 405 allow for the follow up of suspected cases.

406 The opportunity and feasibility described here is not simply theoretical. At the time of publication, 407 several of the Propagate Network partner laboratories (Brazil, France, United States) are promoting or 408 exploring the broad-scale adoption and implementation of this method for ongoing SARS-CoV-2 public 409 health screening efforts in their regions [19]. Additionally, in October 2020, the Infectious Disease 410 Diagnostic Laboratory at the Children's Hospital of Philadelphia implemented an extraction-free protocol 411 for routine diagnostic testing of SARS-CoV-2 (personal communication). In the 3 months following 412 implementation, >40,000 samples were tested using this workflow. The laboratory observed several 413 critical advantages with this approach, including dramatically reduced extraction reagent costs and a 414 halving of the average laboratory turnaround time, despite increasing test volumes. Further, the 415 independence from specialized extraction reagents for routine testing alleviated pressure on supply chains 416 to meet the increased demand. These same positive impacts on testing efficiency are expected to apply to 417 other laboratories that adopt the method.

While no current testing or screening method is optimal to all situations, the direct method should beconsidered as a viable, fit-for-purpose resource to address the growing need for population monitoring

420 during a challenging vaccination rollout and amidst the emergence of increasingly virulent strains of421 SARS-CoV-2.

In addition to the valuable data described above, the global viral testing network established for this study exemplifies the feasibility and importance of establishing transparent, open-access engagements in the public health sciences. Following this study, the Propagate Network will continue to serve as a forum for scientific information exchange and collaboration in the face of future pandemics or health challenges.

426 **5.** Conclusions

427 The need for testing for SARS-CoV-2 continues and in many regions is increasing dramatically. This 428 study provides multisite evidence that the direct RT-PCR method can be employed for the detection of 429 SARS-CoV-2 viral RNA with the omission of the RNA extraction step and its associated extraction 430 reagents. This effort represents the first step toward simplifying detection of SARS-CoV-2 viral RNA for 431 the global research community by leveraging evidence-based guidance such as the results present herein. 432 Many options for detecting SARS-CoV-2 have emerged recently, such as antibody testing, saliva testing, 433 and point-of-care testing, which taken together support the urgent need for actionable viral testing. This 434 work lays the foundation for an adoptable method for future viral outbreaks.

435 Acknowledgments

436 The authors thank and acknowledge Vianney Leclercq (LBM BIOESTEREL, Mouans-Sartoux,

437 France) for assistance in sample analysis and Bob Bruneau (University of Washington, USA) for

438 coordinating international shipping of samples and reagents. The views expressed in this article are those

439 of the author(s) and do not necessarily represent the views or the policies of the U.S. Environmental

440 Protection Agency.

441 Funding

A grant from HESI to the University of Washington supported preparation and shipment of Project A
and B samples to Propagate partner laboratories. Fondecyt provided funding (grant 1201240) for the work
of C. Vial and P. Vial. Grants from the National Institutes of Health National Institute of Allergy and

445	Infectious Diseases (5R01AI129518 and UM1AI068635) and a gift from the MJ Murdock Charitable
446	Trust helped to support the work of University of Washington and Fred Hutchinson Cancer Research
447	Center researchers.

448 **References**

- 1. World Health Organization. COVID-19 strategy update [Internet]. 2020 [cited 24 March 2021].
- 450 Available from: <u>https://www.who.int/publications/m/item/covid-19-strategy-update</u>
- 451 2. Mina MJ, Parker R, Larremore DB. Rethinking COVID-19 test sensitivity a strategy for
 452 containment. N Engl J Med. 2020;383:e120. doi: 10.1056/NEJMp2025631.
- 453 3. Pettit SD, Jerome KR, Rouquié D, Mari B, Barbry P, Kanda Y, et al. 'All In': a pragmatic framework
- 454 for COVID-19 testing and action on a global scale. EMBO Mol Med. 2020;12:e12634. doi:
- 455 10.15252/emmm.202012634.
- 456 4. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in
- 457 suspected human cases. Interim guidance 2 March 2020 [Internet]. 2020 [cited 24 March 2021].
- 458 Available from: <u>https://apps.who.int/iris/handle/10665/331329</u>
- 459 5. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel
- 460 coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:2000045. doi: 10.2807/1560-
- 461 7917.Es.2020.25.3.2000045.
- 462 6. U.S. Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-
- time RT-PCR diagnostic panel for emergency use only: instructions for use [Internet]. 2020 [cited 24
- 464 March 2021]. Available from: <u>https://www.fda.gov/media/134922/download</u>
- 465 7. American Society for Microbiology. Supply shortages impacting COVID-19 and non-COVID testing
- 466 [Internet]. 2021 [cited 24 March 2021]. Available from:
- 467 https://asm.org/Articles/2020/September/Clinical-Microbiology-Supply-Shortage-Collecti-1
- 468 8. Millan C, Navarro A, Kueffner S. Test scarcity means Latin America is 'walking blindly' on virus
- 469 [Internet]. 2020 [cited 24 March 2021]. Available from:

- 470 https://www.bloomberg.com/news/articles/2020-04-08/test-scarcity-makes-tracking-virus-in-latin-
- 471 <u>america-a-crapshoot</u>
- 472 9. Soy A. Lack of Covid-19 testing undermines Africa's 'success' [Internet]. 2020 [cited 24 March

473 2021]. Available from: <u>https://www.bbc.com/news/world-africa-52801190</u>

- 474 10. Bruce EA, Huang ML, Perchetti GA, Tighe S, Laaguiby P, Hoffman JJ, et al. Direct RT-qPCR
- 475 detection of SARS-CoV-2 RNA from patient nasopharyngeal swabs without an RNA extraction step.
- 476 PLoS Biol. 2020;18:e3000896. doi: 10.1371/journal.pbio.3000896.
- 477 11. Smyrlaki I, Ekman M, Lentini A, Rufino de Sousa N, Papanicolaou N, Vondracek M, et al. Massive
- 478 and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR. Nat Commun.
- **479** 2020;11:4812. doi: 10.1038/s41467-020-18611-5.
- 480 12. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-
- 481 CoV-2 Infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081-2090.
- 482 doi: 10.1056/NEJMoa2008457.
- 483 13. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as
- 484 determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from
- 485 infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39:1059-1061. doi: 10.1007/s10096486 020-03913-9.
- 487 14. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al.
- 488 Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19):
- duration and key determinants. medRxiv:2020.2006.2008.20125310 [Preprint]. 2020 [cited 24 March
- 490 2021]. Available from: <u>http://medrxiv.org/content/early/2020/06/09/2020.06.08.20125310.abstract</u>
- 491 15. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological
- 492 assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465-469. doi:
- **493** 10.1038/s41586-020-2196-x.
- 494 16. Graham NR, Whitaker AN, Strother CA, Miles AK, Grier D, McElvany BD, et al. Kinetics and
- isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute

496	respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and
497	disease severity. Clin Transl Immunology. 2020;9:e1189. doi: 10.1002/cti2.1189.
498	17. Kirkland PD, Frost MJ. The impact of viral transport media on PCR assay results for the detection of
499	nucleic acid from SARS-CoV-2. Pathology. 2020;52:811-814. doi: 10.1016/j.pathol.2020.09.013.
500	18. Eshghifar N, Busheri A, Shrestha R, Beqaj S. Evaluation of analytical performance of seven rapid
501	antigen detection kits for detection of SARS-CoV-2 virus. Int J Gen Med. 2021;14:435-440. doi:
502	10.2147/ijgm.S297762.
503	19. Fassy J, Lacoux C, Leroy S, Noussair L, Hubac S, Degoutte A, et al. Versatile and flexible
504	microfluidic qPCR test for high-throughput SARS-CoV-2 and cellular response detection in
505	nasopharyngeal swab samples. medRxiv:2020.2011.2009.20228437 [Preprint]. 2020 [cited 24 March
506	2021]. Available from: https://www.medrxiv.org/content/10.1101/2020.11.09.20228437v1
507	